PolyPeptide Group AG (PLYGF)

OTCMKTS · Delayed Price · Currency is USD

54.42

+11.42 (26.56%)

Jun 10, 2026, 10:13 AM EST

58.89% (1Y)

Market Cap	1.79B +101.1%
Revenue (ttm)	457.12M +15.6%
Net Income	-24.85M
EPS	-0.75
Shares Out	n/a
PE Ratio	n/a
Forward PE	65.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,598
Open	54.42
Previous Close	43.00
Day's Range	54.42 - 54.42
52-Week Range	31.50 - 54.42
Beta	1.04
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1952

Employees 1,440

Stock Exchange OTCMKTS

Ticker Symbol PLYGF

Financial Performance

In 2025, PolyPeptide Group AG's revenue was 389.33 million, an increase of 15.60% compared to the previous year's 336.79 million. Losses were -21.17 million, 8.20% more than in 2024.

Financial numbers in EUR Financial Statements

News

Samsung Biologics (005940) Proposes $1.8 Billion Acquisition of Polypeptide Group

22 days ago - GuruFocus

PolyPeptide Receives CHF 1.46 Bln Samsung Offer, Posts Strong H1 Prelim. Result, Raises Guidance

(RTTNews) - PolyPeptide Group AG (PPGN.SW) on Monday announced that Samsung Biologics Co., Ltd. (207940.KS) will launch an all-cash public tender offer valuing the company at about 1.46 billion Swiss ...

22 days ago - Nasdaq

Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion

22 days ago - GuruFocus

Samsung Biologics To Enter Peptide CDMO Market With CHF 1.46 Bln PolyPeptide Acquisition; Stock Down

(RTTNews) - Samsung Biologics (207940.KS) announced the launch of an all-cash public tender offer to acquire PolyPeptide Group AG(PPGN.SW), a contract development and manufacturing organisation (CDMO)...

22 days ago - Nasdaq

Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal

Samsung Biologics acquires PolyPeptide Group for 2.7 trillion won ($1.8 billion)

22 days ago - CNBC

PolyPeptide downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital downgraded PolyPeptide (PLYGF) to Sector Perform from Outperform with a CHF 44 price target Polypeptide shares have surged beyond the firm’s price target and towards the upper end…

5 weeks ago - TheFly

PolyPeptide price target raised to CHF 38 from CHF 35 at Berenberg

Berenberg analyst Estelle Betrisey raised the firm’s price target on PolyPeptide (PLYGF) to CHF 38 from CHF 35 and keeps a Buy rating on the shares.

2 months ago - TheFly

PolyPeptide price target raised to CHF 40 from CHF 33 at Barclays

Barclays raised the firm’s price target on PolyPeptide (PLYGF) to CHF 40 from CHF 33 and keeps an Overweight rating on the shares.

2 months ago - TheFly

PolyPeptide is attracting takeover interest from EQT, KKR, Bloomberg says

PolyPeptide (PLYGF) Group is attracting private equity takeover interest, with EQT (EQBBF), KKR (KKR), and Advent among suitors looking into a potential acquisition of the company, Dinesh Nair, Allegr...

KKR

4 months ago - TheFly

PolyPeptide Group AG Earnings Call Transcript: H2 2025

2025 saw 16% revenue growth and a sharp EBITDA margin improvement, driven by metabolic therapeutics and capacity expansions. 2026 guidance targets 20%-25% revenue growth and mid to high teens EBITDA margin, with strong customer prepayments and no equity raise planned.

5 months ago - Transcripts